

出國報告（出國類別：開會）

2025 年日本亞太風濕病醫學會聯盟年會 (APLAR 2025 Congress)心得報告

服務機關：高雄榮民總醫院/內科部過敏免疫風濕科

姓名職稱：王愷君/醫師

派赴國家：日本

出國期間：2025/09/02-2025/09/07

報告日期：2025/09/15

摘要

職獲補助參與 2025 年 9 月 3 日至 7 日於日本福岡舉辦之 2025 年亞太風濕病學會聯盟年會 (APLAR 2025 Congress)，並發表關於本科使用 JAK 抑制劑治療類風濕關節炎病患之長期追蹤研究成果。該聯盟成員包含台灣、日本、南韓、澳洲、印度、紐西蘭等超過 30 個成員國，致力於促進與推廣亞太地區風濕疾病相關的科學研究，其官方期刊《International Journal of Rheumatic Diseases》在風濕學研究領域有重要地位。本次大會內容豐富，與會專家除報告各種風濕疾患之臨床研究，各種相關之基礎免疫、細胞及動物實驗、及最新的臨床試驗結果與分析在大會中都有豐富的報告。除亞太地區的與會者外，亦有來自全球的學者專家共襄盛舉，分享經驗與彼此交流，對於職臨床經驗與未來的學術研究助益良多。

關鍵字

類風濕關節炎、JAK 抑制劑

目次

一、目的.....	4
二、過程.....	4
三、心得及建議.....	5
附錄.....	6

一、目的

參與 2025 年亞太風濕病學會聯盟年會，汲取新知，分享本科關於使用 JAK 抑制劑治療類風濕關節炎病患之研究成果，並與世界各國學者交流臨床與研究之經驗。

二、過程

大會第一日(2025/9/3)：

參與骨關節超音波之工作坊，汲取操作經驗與增進臨床技術。

大會第二日(2025/9/4)：

參與骨關節超音波之工作坊，汲取操作經驗與增進臨床技術。

大會第三日(2025/9/5)：

本日參與的 Plenary section 的主題是類風濕關節炎，講者鉅細靡遺地介紹類風濕關節炎目前的治療指引及其證據來源、最新的臨床試驗結果與可期待的嶄新治療機制、以及如何更有效及安全地使用目前現有的傳統疾病修飾藥物。而後發表本科關於以 JAK 抑制劑治療類風濕關節炎病患之長期追蹤經驗之研究海報，與前來觀看海報的各國專家學者進行面對面交流。下午轉往全身性紅斑狼瘡相關講座，對狼瘡相關的病理機轉有更進一步的認識，且也有講者提及如何設計狼瘡相關臨床試驗的有效 endpoint，耳目一新。

大會第四日(2025/9/6)：

本日參與的 Plenary section 主題為全身性紅斑狼瘡，講者除介紹狼瘡患者特有的免疫失調機轉外，亦著重在近期核准及進行臨床試驗中的各種治療方式，並討論如何在現有的證據下使用這些新的治療選項。透過參與國際會議講座，可以察覺與印證風濕免疫疾患的治療仍存在灰色角落與許多不確定性，值得進一步研究與分析。其後參與兒童狼瘡以及發炎性肌炎之相關講座，對於疾病本身與 biomarkers 有更深的認識。

大會第五日(2025/9/7)：

本日 Plenary section 著重於轉譯醫學研究，並以全身性紅斑狼瘡、類風濕關節炎等疾患之不同面向切入探討。從講者的報告中能見證該團隊如何一步一步地揭開免疫疾病的面紗，並驗證其發現，對職未來的研究甚有裨益。其後除參與血清陰性關節炎之講座外，亦觀賞張貼之研究海報，與研究者討論，切磋觀點。

三、心得及建議

非常感謝院方的支持與鼓勵，讓我能於今年參與亞太地區的風濕病國際會議並發表研究成果。透過參與大會汲取最新的研究成果，並與各國學者交流，吸收寶貴的經驗，對職的臨床技術、知識與未來研究甚有助益。

附錄

參與會議證明



CERTIFICATE OF ATTENDANCE

This is to certify that

Dr Kai Chun Wang

has attended the
27th Asia-Pacific League of Associations for Rheumatology Congress (APLAR 2025) from Wednesday 3rd September 2025 to Sunday 7th September 2025

Prof Tsutomu Takeuchi
APLAR President

Prof Yoshiya Tanaka
APLAR 2025 Congress Chair

議程

WED 3 SEP WORKSHOPS		THU 4 SEP WORKSHOPS	FRI 5 SEP CONGRESS DAY 1	SAT 6 SEP CONGRESS DAY 2	SUN 7 SEP CONGRESS DAY 3
	Workshop				
0730-0800	REGISTRATION				
0800-1030	MSK Ultrasound Workshop Day 1 View information here				
1000-1045	BREAK				
1045-1230	MSK Ultrasound Workshop Day 1 (continues) View information here				
1230-1330	BREAK				
1330-1500	MSK Ultrasound Workshop Day 1 (continues) View information here				
1500-1515	BREAK				
1515-1800	MSK Ultrasound Workshop Day 1 (continues) View information here				

WED 3 SEP WORKSHOPS		THU 4 SEP WORKSHOPS		FRI 5 SEP CONGRESS DAY 1		SAT 6 SEP CONGRESS DAY 2		SUN 7 SEP CONGRESS DAY 3		
	Concurrent	Concurrent	Concurrent	Concurrent	Concurrent	Concurrent	Concurrent	Concurrent	Concurrent	
	MSK Ultrasound Workshop Day 2 0800-1030 hours View information here				All about IL-6 inhibition in systemic rheumatic diseases 0900-1030 hours View information here	Clinical Review Course for RMDs 0800-1030 hours View information here		Workshop for GCA, PMR, and TAK 0800-1030 hours View information here		
	BREAK									
	MSK Ultrasound Workshop Day 2 (continues) 1045-1245 hours View information here	GRAPPA Workshop 1045-1245 hours View information here Sponsored by 	Interventional Rheumatology Workshop 1130-1245 hours View information here	How to implement recent guidelines into clinical practice of CTD/SARD-ILDs 1045-1245 hours View information here	Clinical Review Course for RMDs (continues) 1045-1215 hours View information here		Workshop for GCA, PMR, and TAK (continues) 1045-1245 hours View information here			
	LUNCH BREAK									
	MSK Ultrasound Workshop Day 2 (continues) 1330-1630 hours View information here	GRAPPA Workshop (continues) 1330-1600 hours View information here Sponsored by 	Updates and case studies in SLE 1330-1610 hours View information here Sponsored by 	Innovative Approaches in Patient Education in Rheumatology 1330-1630 hours View information here	Clinical Review Course for RMDs (continues) 1400-1630 hours View information here		Workshop for GCA, PMR, and TAK (continues) 1330-1630 hours View information here			
 0-1800	Opening Ceremony Included in registration. View more information here									
1800-1930	Welcome Reception and Official Opening of Exhibition Hall Included in registration. View more information here									

WED 3 SEP WORKSHOPS		THU 4 SEP WORKSHOPS		FRI 5 SEP CONGRESS DAY 1		SAT 6 SEP CONGRESS DAY 2		SUN 7 SEP CONGRESS DAY 3	
	Plenary / Concurrent 1	Concurrent 2	Concurrent 3	Concurrent 4	Concurrent 5	Concurrent 6			
0830-0915		Breakfast symposium 1 Rheumatoid arthritis in the elderly: Characteristics and treatment considerations View Industry Partner Program Sponsored by Bristol Myers Squibb/Ono Pharmaceutical  Bristol Myers Squibb Pharmaceutical View Agenda	Breakfast symposium 2 Biosimilars in rheumatoid arthritis View Industry Partner Program Sponsored by Sandoz  View Agenda	Breakfast symposium 3 Future Directions in MAS and Still's Disease: Challenges and Opportunities View Industry Partner Program Sponsored by Sobi  View Agenda					
0920-1050	Plenary session 1: State of the art rheumatoid arthritis Chairperson: Shin-Seock Lee Managing rheumatoid arthritis in 2025: Update of EULAR recommendations and further trial insights Josef Smolen The changing landscape of rheumatoid arthritis: Pathogenesis and therapy Eleni Gravallese Updates on DMARDs treatment: global standards and regional adaptations AURORA JOURNAL (13) (10)								
1050-1110	 Break and poster viewing								
1110-1215	Morning symposium 1 Time for the AAA approach? Anti-TNF, Anti-JAK, Artificial Intelligence View Industry Partner Program Sponsored by Pfizer  View Agenda	Morning symposium 2 From SLE to LN – preventing organ damage and progression: an Asian perspective View Industry Partner Program Sponsored by GSK  View Agenda	Morning symposium 3 How can rheumatology care be improved in 2025? View Industry Partner Program Sponsored by AbbVie  View Agenda		Morning symposium 5 The Role of Filgotinib in The Treatment of Rheumatoid Arthritis View Industry Partner Program Sponsored by Gilead / Geal Pharmaceuticals  View Agenda	Morning symposium 6 Title coming soon View Industry Partner Program Sponsored by R-Pharm  View Agenda			

1220-1335	Future perspectives of rheumatoid arthritis	Epidemiology <i>Coordinated by the APLAR Epidemiology SIG</i>	Abstract session 1: Mechanism of Rheumatic Diseases	State-of-the-Art SLE	AYR symposium: Musculoskeletal Ultrasound Revolution in rheumatology <i>Coordinated by APLAR Young Rheumatologists</i>	Recent Topics of Sjögren's Disease (SjD): Pathogenesis, Clinical Practice Guidelines (CPGs) and Clinical trials <i>Coordinated by the APLAR Sjogren SIG</i>
	Chairpersons: Yuko Kaneko and Kunihiro Yamaoka At risk or very early RA Peter Taylor D2T-RA, discontinuation of treatments Speaker TBA Q&A	Chairpersons: Nazrul Islam and Srikantiah Chandrashekhara Epidemiology in Rheumatology: Pushing it Forward Evelyn Salido Beyond the Clinic: Public Health Strategies for comprehensive Rheumatic Disease management Nizam Ahmed Comparative Epidemiology of Inflammatory Back Pain and Axial Spondyloarthritis: Insights from Asia-Pacific to North America Muhammad Ahmed Saeed	Chairpersons: Wataru Fujii and TBA The Role of STMN2 in Skin Fibrosis of Systemic Sclerosis and Its Mechanisms Xiaoling Liao Single-cell analysis reveals the immune cell abnormalities underlying the clinical heterogeneity of systemic sclerosis Hiroshi Shimagami Mapping spatially-resolved transcriptomes in systemic sclerosis Minrui Liang Deciphering immune cell heterogeneity in idiopathic inflammatory myopathies via single cell RNA sequencing of peripheral blood Shinji Izuka Identification of Immunofibroblast-Like UBD+ Fibroblasts in Labial Salivary Glands of Primary Sjögren's Disease via RNA Sequencing Saori Abe Investigating T cell dysregulations in peripheral and synovial immune landscapes in Psoriatic Arthritis Alfred Chia Association between ERAP1 polymorphisms and the risk of developing clinical disease in First Degree Relatives of HLA-B27 positive Spondyloarthropathy patients Vishnu Koneru	Chairpersons: Tsuneyo Mimori and Kenji Oku Presentation title TBA Speaker TBA New treatment assessments Eric Morand Precision medicine in Systemic lupus erythematosus Shingo Nakayamada Q&A	Chairpersons: Ghita Harifi and Babur Salim MSK Ultrasound training : From conventional to innovative methods Jemima Albayda Integrating Point-Of-Care Ultrasound in rheumatology practice Bhaskar Dasgupta MSK Ultrasound in the Age of AI: Are We There Yet? Peter Siu Q&A	Chairpersons: Sandhya Pulukool and Atsushi Kawakami Pathogenesis and Recent CPGs for SjD Atsushi Kawakami Understanding of Genetics of Sjögren's disease Maureen Rischmueller Recent clinical trials of molecular targeted agents for Sjögren's Disease Hiroto Tsuboi Clinical and Demographic Characteristics of SjD in Asian Populations Sandhya Pulukool
1340-1510			Lunch symposium 2 Etanercept biosimilar product <i>View Industry Partner Program</i> Sponsored by LG Chem  View Agenda			

1515-1630	Autoimmunity and Precision Medicine	GRAPPA session	Abstract session 2: Treatment Strategy in Rheumatology	Abstract session 3 (Late abstracts)	State-of-the-Art Rheumatology from the Young Generation: AYR, EMEUNET, and J-STAR Collaborative Symposium	Current Trends in Gout Management Coordinated by the APLAR Crystal-induced arthritis SIG
	Chairpersons: Atsushi Kawakami and Yutaka Kawanishi Precision medicine in SLE Nan Shen Single-cell omics based classification of autoimmune rheumatic diseases Masayuki Nishida Immunophenotyping of autoimmune rheumatic diseases Seisaku Kubo Q&A	Chairpersons: Katz Leung and Mitsumasa Kishimoto New developments in PsA Arthur Kavanaugh To lump or split – that is the question Peter Nash Lessons from AXIS Ashish Mathew Discussion	Chairpersons: Ryosuke Hiwa and TBA Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study Yoshiya Tanaka Two-year outcomes of JAK inhibitors: a retrospective cohort analysis from FIRST registry Koshiro Sonomoto Outcomes of Targeting Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non-Inferiority Trial Shin-Seok Lee Spacing of ozoralizumab or methotrexate dose reduction in patients with rheumatoid arthritis achieving target: a randomized, controlled trial (SORAIRD trial) Yuki Inai Efficacy and safety of FiesekZert in acute gouty arthritis: a multicentre, randomized, double-blind, double-dummy, active-controlled study Yu Xue Long-term follow up of efficacy and safety of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study Shogo Matsuda A prospective cohort study to assess incidence of persistence and its predictors in epidemic post-viral arthritis Wulihou Kallery	Session agenda will be made available in due course	Chairpersons: Motomu Hashimoto and Masaru Kato RA & Heat shock proteins Yuriko Yamamura SLE & Type I IFN Antony Psarras DST ARDs & B cells (CAR-T cell therapy) Tamoor Hasan Q&A	Chairpersons: Jose Paulo Lorenzo SGLT2 inhibitors: mechanism and treatment in gout Lisa Stamp Clinical Aspects and Management of Gout Sami Salman Alkheiri A multi-disciplinary approach including patient education – the key to success in gout management Bhik Vaidya Updates from the APLAR gout registry Kanon Jatuworaporn Q&A
1630-1655	Break and poster viewing					

1655-1810	New treatment strategies for SLE Chairpersons: Shinsuke Yasuda and Yurie Setoh Kanda New treatments Laurent Arnaud Treatment recommendation Marta Mosca How to manage complications Andrea Doria Q&A	APLAR – ACR symposium: <i>Coordinated by the ACR – International session</i> Chairpersons: Tsutomu Takeuchi and Glin Seok Lee Update on Epigenetics of Rheumatic Diseases Arr Senelba Aspects of Targeted Therapies Jonathan Kay	Genomics in Rheumatology, Unraveling the Genetic Code of Autoimmune Diseases <i>Coordinated by the APLAR Genetics SIG</i> Chairpersons: Michael Tee and Suleman Khan Immunogenetic Analysis of Systemic Lupus Erythematosus in Kazakhstani Population Lina Zaripova Genetics in Connective Tissue Diseases Oliver Distler Gene Therapies: How Far We Have Gone Suleman Khan Identification of most Detrimental Variants and Potential Therapeutic Targets within IL-2 and IL-3 Genes: An In Silico Approach Fazal Jaffi Q&A	Women's Health & Reproductive Issues in RMDs <i>Coordinated by the APLAR Women's Health & Reproductive Issues & RMDs SIG</i> Chairpersons: Vinod Ravindran and Gemar Al Emadi Inflammatory & non-inflammatory low back pain in Pregnancy Saira Elaine Anwar Khan APLAR Consensus statements for reproductive health in women with AIRDs Vinod Ravindran Recurrent Pregnancy Loss in SLE: Predictors and Prevention Claire Barnett Survey of rheumatologists' awareness and knowledge regarding reproductive rheumatology issues Ghazal Hsieh Q&A	Abstract session 4: Basic Research in Rheumatoid Arthritis Chairpersons: Shuichiro Nakabe and TBA Pathogenic Stromal cells targeting therapy development by RARγ and MTX combination Yuan Liu Anti-carbamylated protein antibodies inhibit histone degradation and contribute to bone erosion in rheumatoid arthritis Shuichiro Nakabe Large-scale multicenter study reveals anti-citrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis Yang Xie Anti-citrullinated procollagen C-endopeptidase enhancer antibody (anti-PCOLCE), a potential biomarker for seronegative rheumatoid arthritis Shuyan Liu Single-cell RNA-seq analysis of synovial CD4^{+} T cells identifies a novel therapeutic target in human rheumatoid arthritis Akinori Murakami Elucidating the synovial pathology underlying treatment resistance in Japanese rheumatoid arthritis patients by multi-omics analysis Risa Yoshikawa Single-cell RNA-seq Analysis of Synovial Fluid in Rheumatoid Arthritis Patients Treated with TNF-α/JAK Inhibitors Unnopsi He	Hot topics in axSpA <i>Coordinated by the APLAR SpA SIG</i> Chairpersons: Faraz Yahya and Muhammad Haroon Sex and Gender Considerations in AxSpA Muhammad Ahmed Saeed Radiographic progression in axSpA: update on the current status Xenosof Baralakos Comorbidities in axSpA: the Asia-Pacific perspective Lai-Shen Tam
1815-1915			Evening symposium 3 Pathophysiology and treatment strategies in systemic lupus erythematosus / Lupus Nephritis View Industry Partner Program Sponsored by Chugai Pharmaceutical  View Agenda	Evening symposium 4 APLAR 2025 Taltz - Evening Symposium View Industry Partner Program Sponsored by Eli Lilly  View Agenda	Evening symposium 5 Oxoralizumab as a Novel Therapeutic Option for Rheumatoid Arthritis in a Super-Aged Society View Industry Partner Program Sponsored by Taiho  View Agenda	Evening symposium 6 Treatment Strategy for Osteoporosis with Rheumatoid Arthritis View Industry Partner Program Sponsored by Daiichi Sankyo  View Agenda
1930-late	AYR Networking Reception (members and invitation only)					

WED 3 SEP WORKSHOPS		THU 4 SEP WORKSHOPS		FRI 5 SEP CONGRESS DAY 1		SAT 6 SEP CONGRESS DAY 2		SUN 7 SEP CONGRESS DAY 3		
	Plenary / Concurrent 1	Concurrent 2	Concurrent 3	Concurrent 4	Concurrent 5	Concurrent 6				
0830-0915		Breakfast symposium 6 Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX View Industry Partner Program Sponsored by medac GmbH / Eisai   View Agenda	Breakfast symposium 7 The importance of IL-6 focusing on Rheumatoid Arthritis and Various Autoimmune-related diseases View Industry Partner Program Sponsored by Chugai Pharmaceutical  View Agenda	Breakfast symposium 8 Title coming soon View Industry Partner Program Sponsored by Asahi Kasei  View Agenda	Breakfast symposium 9 TNF inhibitors in Rheumatoid Arthritis: A Potential Strategy to Mitigate Sarcopenia and Preserve Physical Function View Industry Partner Program Sponsored by J&J Innovative Medicine / Mitsubishi Tanabe Pharma  View Agenda					
0920-1050	Plenary session 2: State of the art systemic lupus erythematosus Chairpersons: TBA and Yoshiya Tanaka Better Medicine for Lupus is here. When will we find it? Juan Merrill Treat to target in SLE: current evidence and future directions Eric Morand State of the art on the use of biological therapies in SLE Marta Mosca									
1050-1110	Break and poster viewing									
1110-1215	Morning symposium 7 What's new for Upadacitinib in Rheumatology in 2025? View Industry Partner Program Sponsored by AbbVie  View Agenda	Morning symposium 8 Current situation of EGPA in Japan View Industry Partner Program Sponsored by GSK  View Agenda	Morning symposium 9 Update on SSC-ILD View Industry Partner Program Sponsored by Boehringer Ingelheim  View Agenda	Morning symposium 10 The role of CANAKINUMAB in the Scleroderma disease treatment paradigm View Industry Partner Program Sponsored by Novartis Pharma K.K.  View Agenda	Morning symposium 11 The mission for remission in SLE: what is now possible for our patients? View Industry Partner Program Sponsored by AstraZeneca  View Agenda	Morning symposium 12 The role and clinical significance of IL-17A and IL-17F in the pathogenesis of SpA View Industry Partner Program Sponsored by UCB Japan Co., Ltd.  View Agenda				

1220-1335	Childhood-onset SLE Coordinated by the APLAR Osteoporosis SIG	Osteoporosis Coordinated by the APLAR Osteoporosis SIG	Digital Health and Telemedicine Coordinated by the APLAR Digital Health and Telemedicine SIG	COPCORD Coordinated by the APLAR COPCORD SIG	Abstract session 5: Clinical Issues in Rheumatic Diseases	Rheumatoid arthritis Coordinated by the APLAR Rheumatoid arthritis SIG
	Chairpersons: Masaaki Mori and Sulaiman Al-Mayouf Pediatric SLE Guidelines in Japan Masaaki Mori Adult and Childhood-onset Lupus: Same yet Different Pauline Chan Monogenic Lupus: Lessons from an International Cohort Sulaiman Al-Mayouf CAR-T therapy on Childhood-onset refractory SLE Meiping Lu Q&A	Chairpersons: Julie Li-Yu, MD and Sumapa Chalarnnuay Osteoporosis sequencing therapy from UoC perspective Mustafa Al Izzi TBS and clinical applications (comparing 2 guidelines) Sumapa Chalarnnuay Fracture liaison service in Qatar, benefits and challenges Nabeel Abdulla Q&A	Chairpersons: Sakir Ahmed and Lisa Trabuco Real world applications of digital health technologies in spondyloarthritis Georg Schett How to use AI to optimize your EMR Byeongzu Ghang Q&A SIG updates (2024-25) and plans for the coming year Feedback	Chairpersons: Ashish Mathew and William Taylor Impact of type 2 diabetes mellitus on the prevalence, clinical presentation and outcome of common musculoskeletal diseases at the community level in Bangladesh Sabrina Yesmin Prevalence, Risk Factors, and Quality of Life of Knee Osteoarthritis in Urban Community in Indonesia: A COPCORD Study Pande Ketut Kumari Sinarkoro Rapid urbanisation and temporal trends in MSK disorders in China Lai-Shan Tam Q&A	Chairpersons: Mitsumasa Kishimoto and TBC Longitudinal Trends in Unmet Needs in Systemic Lupus Erythematosus: A Decade of Insights from the Asia Pacific Lupus Collaboration Rangi Kandaneerathnayake Unveiling distinct subgroups of non-remission patients with SLE – a cluster analysis of a multi-centre longitudinal cohort Chiu Wai Shirley Chan Barriers to biologic treatment in patients with systemic lupus erythematosus: Results from a real-world study in Japan and China Hidetaka Kameda Predicting Disease State in Patients with Systemic Lupus Erythematosus using Digital Biomarkers from Wearable Devices Tomoko Niwano Maternal connective tissue disease and the risk of childhood mental disorder: A population-based cohort in Taiwan Yachun Huang Presentation title TBA Speaker TBA Gaps in Training and Expertise in Myositis Outcome Measures: Insights from the 2024 MCTG Investigators' Survey Ting-yuan Lan	Chairpersons: Zhan-guo Li and Kunihiko Yamaoka Basic research on RA Fanlei Hu APLAR RA recommendation Kunihiko Yamaoka The Rheumatoid Arthritis Patient Registry: Implications for Clinical Practice, Research and the Health System Togizbaev Galymzhan Asylbekovich Q&A
1340-1510			Lunch symposium 7 The current screening, monitoring, and treatment for RA-ILD View Industry Partner Program Sponsored by Boehringer Ingelheim  View Agenda	Lunch symposium 8 Go Beyond T2T with harmony View Industry Partner Program Sponsored by Eli Lilly & Company  View Agenda		

1515-1630	State-of-the-Art rheumatoid arthritis Chairpersons: Isao Matsuno and Shintaro Hirata The Role of Age-Associated ThA Cells in Autoimmune Diseases Yoshitaka Okumura Translational medicine Shiroo Nakayama Organ involvement Peter Taylor Q&A	LJRD session Coordinated by the International Journal of Rheumatic Diseases Chairpersons: James Wei and Shin-Seok Lee Global burden and trends of rheumatic diseases Chih-Sing Lee Role of APLAR in worldwide rheumatology Takuma Takeuchi (Taka Take) How to enhance the journal impact of LJRD? James Wei Q&A	Navigating the complexities of systemic sclerosis Coordinated by the APLAR Subcommittee SSC Chairpersons: Andrea Low and Ching-Ching Faochisan Emerging concepts and updates on management of primary heart involvement in systemic sclerosis Luana Rossi Updates on the management and treatment of pulmonary hypertension in systemic sclerosis Hidetaka Yasuda Cell therapy in systemic sclerosis: Lessons learnt from oncology to autoimmunity Francesca Lim	Deep Dive into IIM: From Trials to Bedside Coordinated by the APLAR Myositis (IM) SIG Chairpersons: Yoshiyuki Urayama and Choon Guan Chae Biomarkers in IM Luca Laccarino Subclassification/Endotyping of IM Guochun Wang Management Recommendations of IM Takafusa Goto Q&A	Abstract session 6: Pathogenesis of Rheumatic Diseases Chairpersons: Haruka Tsuchiya and TBA Immunological characterization of ThA cells in SLE pathogenesis using single-cell RNA and TCR sequencing Hiroyuki Teruya Precision Liquid Biopsy for Lupus Nephritis, cfDNA Methylation and Fragmentomics Signatures Enable Non-invasive Diagnosis and Dynamic Disease Tracking Qiong Li Epigenetic profiling of age-associated helper CD4+ T cell subset, ThA cells, in autoimmune diseases - Manaka Goto Single-cell analysis of immunological features of adverse pregnancy outcomes in women with systemic lupus erythematosus Kaigo Terada Deciphering state-dependent immune features at single-cell resolution from multi-layer omics including transcriptomics, genome variants, modic chromosomal alterations, and plasma proteomics Ryuya Edahiro Vascular effects of achieving low disease activity in axial spondyloarthritis – a 2-year prospective cohort study Huan Meng X-linked Hemizygous DOCK11 Mutation Masquerading as Systemic Juvenile Idiopathic Arthritis: A Case Report Anna Sologub	Therapeutic advances in SLE Coordinated by the APLAR SLE SIG Chairpersons: Laxmyoti Hanjioyo and Alberta Hoi Biological therapies for systemic lupus erythematosus and lupus nephritis Yoshiya Tanaka CAR-T and cellular therapies for SLE Thomas Sze Yan Chan Targeted small molecules and newer immunosuppressive drugs for SLE Chi Chiu Mok
1630-1655	Break and poster viewing					
1655-1810	Surgery of rheumatoid foot and ankle Chairpersons: Yasuharu Nakashima and Yoshi Mochida Joint preserving surgery for rheumatoid forefoot deformity Keisaku Yano Presentation title TBA Lee Schon Q&A	APLAR – EULAR symposium Coordinated by EULAR – International session Chairpersons: Laxmyoti Hanjioyo and Yoshiya Tanaka AI is to make imaging more efficient for patients with RA Daniel Altmann RA imaging: what is new? Annamaria Iagnocco Difficult-To-Treat axial Spondyloarthritis: a real problem or just semantics? Ken-ichi Suzuki	Paediatric Coordinated by the APLAR Paediatric SIG Chairpersons: Priscilla Campbell-Stokes and Elizabeth Ang Paediatric Rheumatology Challenges in Asia-Pacific Sumaira Farman APLAR JA guidelines Thaschawan Arachcharit Redefining Treatment: Multitarget Approaches for Difficult-To-Treat Paediatric Lupus Nephritis Christine Bernal Takayasu/Vasculitis: Lessons Learnt Satish Kumar Q&A	Social Commitment & Patient Outreach Coordinated by the APLAR Social Commitment & Patient Outreach SIG Chairpersons: Mighty Ahmad and TBC Introduction Hajet Mir Ahmad Delay in diagnosis and initiation of treatment due to shortage of workforce in the Asia-Pacific Syed Aliqul Haq Workforce Productivity and Economic Costs of Rheumatic Diseases Chengyuan Karadichanta Driving safe and effective care through clinical care standards Catherine Hill Q&A	Pathophysiology of Arthritis and Osteoimmunology Chairpersons: Kazuhito Saitoh and Rahim Handa Presentation title TBA Norio Komatsu Presentation title TBA Masaru Ishii Dynamics of bone loss in Rheumatoid Arthritis and Psoriasis Arthritis Georg Schett Q&A	Cutting edge in vasculitis Coordinated by the APLAR Vasculitis SIG Chairpersons: Xinping Tian and Masaru Ishii Clinical insights from immunological phenotypes of microscopic polyangiitis Masayuki Nishida Eosinophilic granulomatosis with polyangiitis—from pathogenesis to targeted therapy Hajer Dinekenel Polymyalgia rheumatica—clinical assessment, imaging, and new treatment Rhakesh Dasgupta Q&A
1900-late	Joint Presidential Gala dinner					

WED 3 SEP WORKSHOPS		THU 4 SEP WORKSHOPS		FRI 5 SEP CONGRESS DAY 1		SAT 6 SEP CONGRESS DAY 2		SUN 7 SEP CONGRESS DAY 3	
	Plenary / Concurrent 1	Concurrent 2	Concurrent 3	Concurrent 4	Concurrent 5	Concurrent 6			
0800-0915	Breakthrough Therapies and Emerging Challenges in Systemic Autoimmune Diseases	Advances in Imaging in Rheumatology <i>Coordinated by the APLAR Imaging SIG</i>	Surgery of rheumatoid hand and elbow	Management of lung complications in CTDs: Moving forward	Updates on OA therapy <i>Coordinated by the APLAR Osteoarthritis SIG</i>	SLE: Comorbidities and less common manifestations <i>Coordinated by the APLAR SLE SIG</i>			
	Chairpersons: Shingo Nakayama and Yoshiya Tanaka Molecular targeted therapies Richard Furie CAR-T and TCE Georg Schett Q&A	Chairpersons: Kok-Wei Kong and Ha-Wing Gavin Lee New advances in nuclear radionuclide scanning including PET for patients with rheumatic diseases Hiroyuki Yanagihata New sequence and other technological advancement in MRI relevant to the field of rheumatology Gervais Wansai Cheong MSK USG – what has been learned in past one year (a year review in literature) Jemima Felicity Abeyde	Chairpersons: Nobumori Takahashi and Toshihisa Kajima Presentation title TBA Keiichiro Nishida Difficult-to-treat Rheumatoid Arthritis (D2T RA) and Surgical Management of the Hand Hajime Ishikawa Q&A	Chairpersons: Takao Fujii and Ayako Nakajima CTD-PWH: how anti-remodeling drugs change treatment landscape Dinesh Khanna CTD-ILD: Personalized treatment based on risk stratification Andrea Low Hsu Ling Management of pulmonary hypertension associated with interstitial lung disease in patients with systemic autoimmune rheumatic diseases Masataka Kuwana Q&A	Chairpersons: Matthew Jang and Mohsen Soroush Barriers to implementation of OA guidelines Imeshi Anukorals OA and semaglutide Sheeta Nakarmi IL-23 and CCL17 in OA Kevin Lee Q&A	Chairpersons: Chi-Chia Mok and Kenji Oku Assessment and management of osteoporosis and avascular necrosis Sandra Navarra Assessment and management of neuropsychiatric lupus Alberta Hoi Management of thrombotic and diabetic APS in SLE Kenji Oku			
0920-1050	Plenary session 3: State of the art translational research Chairpersons: Tatsuya Takeuchi and Shingo Nakayama Human Lupus: An Interferonopathy with Many Twists Virginia Pascual Deep Depletion of B-cells as treatment of autoimmune disease Georg Schett Therapeutic Targeting of the Angio-lymphokine PIGF in Rheumatoid Arthritis Wan-UK Kim								
1050-1110	Break and poster viewing								

1050-1110	Break and poster viewing					
1110-1225	Breakthrough Genetics and Emerging Challenges in Systemic Autoimmune Diseases Chairpersons: Kazuhiko Yamamoto and Chikashi Terao Elucidation of intractable pathophysiology of rheumatoid arthritis using multi-omics technologies Hanaka Tsuchiya Distribution of gut, endogenous, and exogenous viruses to systemic lupus erythematosus Yukinori Okada Multi-omics Nan Shen Q&A	Abstract session 7: New Horizons in the Treatment of SLE Chairpersons: Michihito Kano Kidney-related outcomes with Obinutuzumab in patients with active lupus nephritis: A pre-specified exploratory analysis of the Registry study Richard Hark Wide-angled serum metabolomics reveals associations with clinical phenotype and glucocorticoid use in systemic lupus erythematosus Laura Tades Raised von Willebrand Factor, Antigen and Clot Waveform Analysis demonstrate increased Endothelial Dysfunction and Hypercoagulability in SLE patients with APS Yi Wye Lai Allogenic CD19 CAR-NK Cell Therapy in Refractory Systemic Lupus Erythematosus-A Case Series Study Je Goo Presentation title TBA Speaker TBA Preliminary Safety, Efficacy, and Cellular Kinetics of CSA213, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus Jiangao Ren Assessment of the functional activity of the CD19-specific CAR-T cells in immunosuppressive patients with various rheumatic diseases in vitro Vibali Omelchenko	Systemic JIA Chairpersons: Takako Miyamae and Seemant Vilayth Current status and future prospects of clinical practice for systemic juvenile idiopathic arthritis in Japan Masaki Shimizu The CARIA Registry systemic JIA cohort: Clinical patterns, outcomes and treatment in North America Yakiko Kimura Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome Chiaeng Li From Diagnosis to Treatment: Applying the EULAR/TRAIS 2024 Recommendations in Clinical Practice for Still's Disease – with <i>Levodopa</i> for Limited-Resource Settings Seemant Vilayth Q&A	Interventional rheumatology Chairpersons: Shigeki Momohara and Yuka Kadono Endoscopic spinal surgery for RA Hideki Nakamoto Arthroscopic surgery for RA Natsuko Nakagawa Cooled Radiofrequency Ablation of Genicular Nerves Seong-Soo Choi Q&A	Inborn Errors and Somatic Mosaicism in Adult Autoinflammatory Diseases Chairpersons: Masaru Kato and Atsushi Kawahara Overview of monogenic autoinflammatory diseases Krista Gutierrez Rubio Single-cell omics based approach in Japanese FMP-10 mice Yamashita Kaga Characterization of Japanese VISA syndrome from nationwide registry Yohai Kikino Q&A	State-of-the-Art spondyloarthritis Chairpersons: Ipppei Miyagawa and Hidetaka Komeda Presentation title TBA Speaker TBA HYPERMASON SRA TBA Ipppei Miyagawa Hot topics in AxSpA Peter Nash Q&A
1225-1325						
1325-1440	Historical Perspectives in Rheumatology Chairpersons: Kazuhiko Yamamoto and Syed Atiqul Haq Alfred Nobel and his legacy to Rheumatology Kaashik Chaudhuri William Osler and the Rheumatologist of today Robini Handa Philip Hench and the discovery of Glucocorticoids: Lessons from the past with implications for the future Frank Buttgereit Q&A	Abstract session 8 (Late abstracts) Session agenda will be made available in due course	Cutting-edge of Trans-omics Studies on Rheumatic Diseases Chairpersons: Hanaka Tsuchiya and Sei Ochi Analysis of Somatic Mutations in Immune Cells in Rheumatic Diseases Keishi Fujie Projecting trans-omics of autoimmune diseases into single cell resolution Yukinori Okada Clinical Application of Omics Studies in SLE towards Precision Medicine Sang-Chul Bae Q&A	Pathological skills for rheumatologists Chairpersons: Naoto Tanaka and Hiroaki Yokouchi Lupus nephritis Keiju Hirakawa Presentation title TBA Speaker TBA Q&A	Managing safety of JAK inhibitors Chairpersons: Masayoshi Harigae and Akie Morimoto Safety of JAK Inhibitors in Rheumatoid arthritis: Post-marketing surveillance in Japan Masataka Kimura Infection CC Mok Current Perspectives on Malignancy Risk Associated with JAK Inhibitors in Rheumatic Diseases Soo Kyung Cho Q&A	Pros or cons of glucocorticoid for systemic autoimmune diseases Chairpersons: Tatsuya Atsumi and Kazuhisa Nakano Lupus nephritis recommendations: efforts to minimise glucocorticoids use Maria Tektonidou Presentation title TBA Speaker TBA Q&A
1440-1515	Closing ceremony and awards					



27th Asia-Pacific League of Associations for Rheumatology Congress

Fukuoka, Japan | 3-7 September 2025



Long-term Effectiveness and Drug Survival of JAK Inhibitors in Rheumatoid Arthritis: A 13-Year Single-Center Study Comparing First-Line and Non-First-Line Users

Kai-Chun Wang^{1,2}

¹Division of Allergy-Immunology-Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

²The Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan

Purpose

To evaluate the long-term effectiveness and drug survival of JAK inhibitors (JAKi) in rheumatoid arthritis (RA), comparing outcomes between first-line and non-first-line users.

Methods

A retrospective review was conducted between 2010 and 2023 on 1,167 RA patients treated with biologic or targeted synthetic DMARDs (b/tsDMARDs). Among them, 89 patients received JAKi, categorized into **first-line and non-first-line users**. Demographic data and outcomes were compared.

Results

Of the 89 RA patients, 49 (55.1%) were first-line JAKi users, and 40 (44.9%) were non-first-line users (Table 1). Disease duration before initiating JAKi was shorter in first-line users (7.12 ± 6.24 vs 9.67 ± 4.62 years, $p = 0.034$). DAS28-ESR was significantly higher in the first-line group (5.98 ± 0.83 vs 5.35 ± 1.03 , $p = 0.003$). Tofacitinib was most commonly used (75.5% first-line, 60% non-first-line). Among non-first-line users, 85% had received one prior bDMARD, and 15% had received two. The DAS28-ESR at 6 months was 3.79 ± 0.62 , showing improvement without significant differences between tofacitinib, baricitinib, and upadacitinib. The cumulative survival rate for JAKi at 108 months was 66%, with no significant difference between JAKi types or between first-line and non-first-line users (Figures A and B). However, among non-first-line users, drug survival at 38 months was significantly lower for tofacitinib compared to upadacitinib (54% vs. 100%, $p = 0.017$), whereas no significant difference was observed among first-line users (Figures C and D). Secondary failure (46%) was the most common reason for discontinuation, followed by adverse events (18%) and malignancies (18%). All patients who failed the first JAKi switched to a bDMARD with a different mechanism of action in our cohort.

Conclusion


JAK inhibitors remained effective even when initiated later in the disease course, including among non-first-line users. While drug survival was comparable among first-line users, tofacitinib showed lower drug survival in non-first-line users. These findings may help guide treatment decisions, particularly in selecting appropriate JAK inhibitors for patients with prior treatment exposure.

✉ kcwang@vghks.gov.tw


Demography and characteristics of RA patients undergoing JAKi therapy

Characteristic	RA patients received JAKi (n=89)	1st line JAKi (n=49)	Non-1st line JAKi users (n=40)	P
Female sex, n (%)	76 (85.4%)	42 (85.7%)	34 (85.0%)	0.924
Age at RA diagnosis (years)	45.12 ± 13.77	46.1 ± 14.60	43.9 ± 12.36	0.461
Disease duration till initiating JAKi (years)	8.27 ± 5.69	7.12 ± 6.24	9.67 ± 4.62	0.034*
Baseline ESR (mm/hr)	42.8 ± 29.69	40.57 ± 28.28	45.69 ± 31.61	0.440
Baseline CRP (mg/dL)	2.46 ± 2.57	2.54 ± 2.44	2.36 ± 2.75	0.752
Baseline DAS28-ESR	5.71 ± 0.97	5.98 ± 0.83	5.35 ± 1.03	0.003*
RF positivity, n (%)	64/88 (72.7%)	34 (77.6%)	26/39 (66.7%)	0.255
ACPA positivity, n (%)	65/81 (80.2%)	37/45 (82.2%)	28/36 (77.8%)	0.618
Smoking, n (%)	4 (4.49%)	1 (2%)	3 (7.5%)	0.216
Comorbidities, n (%)				
Hypertension	35 (39.33%)	20 (40.8%)	15 (37.5%)	0.750
Dyslipidemia	26 (29.21%)	13 (26.5%)	13 (32.5%)	0.538
Diabetes mellitus	9 (10.11%)	6 (12.2%)	3 (7.5%)	0.480
Chronic kidney disease, stage 3-5	4 (4.49%)	3 (6.1%)	1 (2.5%)	0.432
Coronary artery disease	1 (1.12%)	1 (2%)	0 (0%)	0.364
Cancer/malignant disease	1 (1.12%)	1 (2%)	0 (0%)	0.364
b/tsDMARDs prior to JAKi, n (%)				N/A
0	49 (55.06%)	49 (100%)	0 (0%)	
1	34 (38.20%)	0 (0%)	34 (85%)	
2	6 (6.74%)	0 (0%)	6 (15%)	
JAKi, n (%)				0.011*
Tofacitinib	81 (88.54%)	37 (75.51%)	24 (60%)	0.117
Baricitinib	11 (12.36%)	8 (16.32%)	3 (7.5%)	0.208
Upadacitinib	17 (19.10%)	4 (8.16%)	13 (32.5%)	0.002*
JAKi failure, n (%)	28 (31.46%)	18 (36.73%)	10 (25%)	0.236
Switch, n (%)				
1st	24/28 (85.71%)	16/18 (88.89%)	8/10 (80%)	
2nd	7/24 (29.17%)	5/16 (31.25%)	2/8 (25%)	
3rd	11/24 (45.83%)	8/16 (50%)	5/8 (62.5%)	
Abatecept	2/24 (8.33%)	0/16 (0%)	2/8 (25%)	
IL6 inhibitors	4/24 (16.67%)	3/16 (18.75%)	1/8 (12.5%)	
CycL, n (%)	0/28 (0%)	0/18 (0%)	0/10 (0%)	
No further b/tsDMARDs, n (%)	4/28 (14.29%)	2/18 (11.11%)	2/10 (20%)	

Drug survival of JAK inhibitors in patients with RA



APLAR 2025




CERTIFICATE OF APPRECIATION

This is to certify that

Dr Kai Chun Wang

presented during the official program at the
27th Asia-Pacific League of Associations for Rheumatology
Congress (APLAR 2025) from Wednesday 3rd September 2025
to Sunday 7th September 2025


Prof Tsutomu Takeuchi
APLAR President


Prof Yoshiya Tanaka
APLAR 2025 Congress Chair

大會照片





